For a long time researchers have lacked truly disease-relevant models of Parkinson’s.
We have loaded cells with toxins to cause cell death, we have loaded cells with mutant proteins to cause cell death, we have loaded cells with… well, you get the idea. Long story short though, we have never had proper models of Parkinson’s – that is a model which present all of the cardinal features of the condition (Lewy bodies, cell loss, and motor impairment).
The various models we have available have provided us with a wealth of knowledge about the biology of how cells die and how we can protect them, which has led to numerous experimental drugs being tested in the clinic. But there has always been a linger question of ‘how disease-relevant are these models?’
This situation may be about to change.
In today’s post we will look at new research in which Japanese researchers have genetically engineered mice in which they observed the generation of Lewy bodies, the loss of dopamine neurons and motor impairments. We will look at how these mice have been generated, and what it may tell us about Parkinson’s.
Walt Disney. Source: PBS
Ok, before we start today’s post: Five interesting facts about the animator Walt Disney (1901 – 1966):
- Disney dropped out of high school at age 16 with the goal of joining the Army to help out in the war effort. He was rejected for being underage, but was able to get a job as an ambulance driver with the Red Cross in France.
- From 1928 (the birth of Mickey Mouse) until 1947, Disney himself performed the voice of Mickey.
- Mickey Mouse was originally named “Mortimer Mouse”, but it was Disney’s wife who suggested that the name Mortimer sounded too pompous (seriously, can you imagine a world with the “Mortimer Mouse show”?). She convinced Disney to change the name to Mickey (the name Mortimer was later given to one of Mickey’s rivals).
- To this day, Disney holds the record for the most individual Academy Awards and nominations. Between 1932 and 1969, he won 22 Academy Awards and was nominated 59 times (Source).
- And best of all: On his deathbed as he lay dying from lung cancer, Disney wrote the name “Kurt Russell” on a piece of paper. They were in effect his ‘last words’. But no one knows what they mean. Even Kurt is a bit perplexed by it all. He (along with many others) was a child actor contracted to the Disney company at the time, but why did Walt write Russell’s name as opposed to something more deep and meaningful (no disrespect intended towards Mr Russell).
Actor Kurt Russell. Source: Fxguide
When asked why he thought his great creation “Mickey mouse” was so popular, Walt Disney responded that “When people laugh at Mickey Mouse, it’s because he’s so human; and that is the secret of his popularity”.
Mickey Mouse. Source: Ohmy.Disney
This is a curious statement.
Curious because in biomedical research, mice are used in experiments to better understand the molecular pathways underlying basic biology and for the testing of novel therapeutics, and yet they are so NOT human.
There are major biological differences between us and them.
Not human. Source: USNews
It has been a major dilemma for the research community for some time with regards to translating novel therapies to humans, and it raises obvious ethical questions of whether we should be using mice at all for the basic research if they are so different from us. This problem is particularly apparent in the field of immunology, where the differences between ‘mice and men’ is so vast in some cases that researcher have called for moving away from mice entirely and focusing on solely human models (Click here and here for a good reads on this topic).
What does this have to do with Parkinson’s?
Well, we for a long time we have struggled with this same problem in the field of Parkinson’s research.
Traditional rodent models of Parkinson’s involved the delivery of neurotoxins to the dopamine neurons in the brain, which killed those cells and rendered the animals behaviourally ‘Parkinsonian’. More recently, the dopamine neurons have been stressed by the over-production of disease-associated proteins (like alpha synuclein), and this has been shown to result in cell death.
But this has begged the obvious question: how Parkinson’s-relevant are these models? (neurotoxins and over-dose of protein)
Some (myself included) would suggest ‘not very, but they are the best we have at the moment’.
This is a weak answer I’ll agree, but as I suggested in the intro above, this may be about to change. This week saw the publication of an interesting research report:
Title: Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice.
Authors: Sato S, Uchihara T, Fukuda T, Noda S, Kondo H, Saiki S, Komatsu M, Uchiyama Y, Tanaka K, Hattori N.
Journal: Sci Rep. 2018 Feb 12;8(1):2813.
PMID: 29434298 (This article is OPEN ACCESS if you would like to read it)
In this study, Japanese researchers have generated genetically engineered mice which lose dopamine neurons, exhibit motor complications as they age, AND appear to develop Lewy bodies – raising the possibility that this could represent a very Parkinson’s-relevant model.
Hang on a second, remind me again: what is a Lewy body?
A definitive diagnosis of Parkinson’s can only be made at the postmortem stage with an examination of the brain. Until that moment, all cases of Parkinson’s are ‘suspected’. When a neuropathologist makes an examination of the brain of a person who passed away with the clinical features of Parkinson’s, there are two characteristic hallmarks that they will be looking for in order to provide a final diagnosis of the condition:
1. The loss of specific populations of cells in the brain, such as the dopamine producing neurons in a region called the substantia nigra, which lies in an area called the midbrain (at the base of the brain/top of the brain stem). As the name suggests, the substantia nigra region is visible due to the production of a ‘substance dark’ molecule called neuromelanin in the dopamine neurons. And as you can see in the image below, the Parkinsonian brain has less dark pigmented cells in the substantia nigra region of the midbrain.
The dark pigmented dopamine neurons in the substantia nigra are reduced in the Parkinsonian brain (right). Source:Memorangapp
2. Dense, circular clusters (or aggregates) of protein within cells, which are called Lewy bodies.
A cartoon of a neuron, with the Lewy body indicated within the cell body. Source: Alzheimer’s news
A Lewy body is referred to as a cellular inclusion, as they are almost always found inside the cell body. They generally measure between 5–25 microns in diameter (5 microns is 0.005 mm) and thus they are tiny. But when compared to the neuron within which they reside they are rather large (neurons usually measures 40-100 microns in diameter).
A photo of a Lewy body inside of a neuron. Source: Neuropathology-web
How do Lewy bodies form? And what is their function?
The short answer to these questions is:
The longer answer is: Our understanding of how Lewy bodies are formed and their actual role in neurodegenerative conditions like Parkinson’s is extremely limited.
And this is why the research report from the Japanese scientists is so interesting. They genetically engineered mice that had no ATG7 (or Autophagy Related 7) protein in their dopamine neurons. And by removing just this one protein, they observed the appearance of “Lewy bodies”.
What is ATG7?
ATG7 is an enzyme that is essential for the process of autophagy.
And yes, I know what you are going to ask next: what is autophagy?
Autophagy is an absolutely essential function in a cell. Without autophagy, old proteins would pile up making the cell sick and eventually causing it to die. Through the process of autophagy, the cell can break down the old protein, clearing the way for fresh new proteins to do their job.
Think of autophagy as the waste disposal/recycling process of the cell.
The process of autophagy. Source: Wormbook
Waste material inside a cell is collected in membranes that form sacs (called vesicles). These vesicles then bind to another sac (called a lysosome) which contains enzymes that will breakdown and degrade the waste material. The degraded waste material can then be recycled or disposed of by spitting it out of the cell.
And without ATG7, this autophagy/waste disposal system breaks down.
So what happened in these mice with no waste disposal system in their dopamine neurons?
The genetically engineered mice that had no ATG7 in their dopamine neurons looked perfectly normal, until approximately 100 weeks of age. Understand that mice live for 2 years on average, so this is late age for these mice. The mice began to show issues with motor coordination tasks at 100 weeks of age, and then more serious motor deficits became apparent at 110 weeks. As you can see in the image below, the mice with no ATG7 in their dopamine neurons (the Atg7 F/F:TH-Cre mice) demonstrated a significant increase in foot slipping when they walking across a beam:
When the researchers looked at the dopamine neurons in their mice, they found no Lewy body-like aggregates at the age of 18 months in the control mice (Atg7flox/flox – which have normal levels of Atg7). But in the mutant mice (Atg7flox/flox:TH-Cre mice – those without Atg7 in the dopamine neurons), at just 2 months of age they observed inclusions starting to form. The researchers looked at the levels of a protein called p62 in these mice. p62 is a receptor for waste destined to be degraded by autophagy, and in the absence of Atg7, p62 started to build up at just 2 months of age in the mutant mice. In 18-month-old mutant mice, these p62 inclusions were larger and mainly located outside the body of the cells and mainly in their branches (neurites).
p62 in the dopamine neurons. Source: Nature
Interestingly, many of these aggregates contained both the Parkinson’s-associated protein alpha synuclein and lots of mitochondria. Mitochondria are the power stations of the cell, and when they are worn out or damaged they are disposed of via autophagy. But as you can see in panel C of the image below, the dark shapes of mitochondria are clearly visible within the Lew body-like inclusion (white arrows; inclusions are labeled with a dashed line):
The presence of old mitochondria within Lewy bodies from postmortem sections of Parkinsonian brain has recently been described in a research report that was posted last year on the preprint website BioRxiv:
Title: Lewy pathology in Parkinson’s disease consists of a crowded organellar membranous medley
Authors: Shahmoradian SH, Genoud C, Graff-Meyer A, Hench J, Moors T, Schweighauser G, Wang J, Goldie KN, Sütterlin R, Castaño-Díez D, Pérez-Navarro P, Huisman E, Ipsen S, Ingrassia A, de Gier Y, Rozemuller AJM, De Paepe A, Erny J, Staempfli A, Hoernschemeyer J, Großerüschkamp F, Niedieker D, El-Mashtoly SF, Quadri M, van IJcken WFJ, Bonifati V, Gerwert K, Bohrmann B, Frank S, Britschgi M, Stahlberg H, van de Berg WDJ, Lauer ME
Journal: bioRxiv preprint first posted online May. 16, 2017
PMID: N/A (This article is OPEN ACCESS if you would like to read it)
Using multiple microscopic imaging techniques, the investigators of this preprint discovered that the interior of Lewy bodies is actually a crowded mess of membranes from vesicles (the bags in which proteins are transported around cells – the aqua blue arrows in the image below), old & deformed mitochondria (the orange arrows in the image below) and disrupted structural elements of the cells (various proteins). This was in complete contrast to the expected filaments.
High magnification image of a Lewy body from a PD brain. Source: Biorxiv
The Japanese investigators also found that the number of dopamine neurons decreased in aged mutant mice (Atg7 flox/flox:TH-Cre), which may have contributed to the locomotor dysfunction that they observed. They also found a reduction in the levels of dopamine in the striatum (a region of the brain where the bulk of dopamine is released).
Admittedly, the level dopamine cell loss is a small percentage of the whole, but the reduction in the levels of dopamine being released is large. This difference could indicate addition dysfunction in the dopamine neurons with regards to their functioning – that is, the cells may remain alive, but they are struggling to do their job.
This study has presented compelling data that the loss of normal autophagy in dopamine neurons can lead to movement issues, cell loss and the development of Lewy body-like structures.
And remarkably, the study is supported by previous work by an independent research group that investigated these same mice (Atg7 flox/flox:TH-Cre) and found very similar results:
Title: Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α-synuclein and LRRK2 in the brain.
Authors: Friedman LG, Lachenmayer ML, Wang J, He L, Poulose SM, Komatsu M, Holstein GR, Yue Z.
Journal: J Neurosci. 2012 May 30;32(22):7585-93.
PMID: 22649237 (This article is OPEN ACCESS if you would like to read it)
In this study, researchers from the Friedman Brain Institute (Mount Sinai School of Medicine, New York) found that Atg7 flox/flox:TH-Cre mice developed intracellular p62 inclusions in dopamine neurons, as well as a delayed loss of dopamine neurons (39% at 9 months of age) and locomotor impairments (significant issues also at 9 months of age). They did not look at these mice at later stages of life (as the Japanese researchers above did), which may explain why this study did not note the more “Lewy body”-like structures.
So what does it all mean?
Japanese researchers have presented data on a genetically engineered mouse which indicates that disruption of the autophagy process in dopamine neurons leads to a more bona fide model of Parkinson’s, with delayed locomotor issues, dopamine cell loss and the appearance of “Lewy body”-like structures in the cells (all the hall marks of the human condition).
While these new results suggesting that a mouse can develop “Lewy bodies” are very interesting, further characterisation are required and would be extremely enlightening – especially with regards as to how the cellular inclusions actually develop. A direct microscopic comparison of these mouse “Lewy bodies” with Lewy bodies from post mortem sections of brain from people who passed away with Parkinson’s would also be desired.
If these mouse Lewy bodies are found to be the real thing, this genetically engineered mouse could be a powerful new tool for the Parkinson’s research community. Of particular interest would be the testing of new (or repurposed) drugs in these mice. A drug that could reduce the Lewy body burden and cell loss in these mice would certainly be worth clinically testing.
And if the disruption of the autophagy process is found to be an underlying process in the human condition of Parkinson’s, it begs an obvious question: what causes the disruption in autophagy?
Answer that question and I’ll nominate you for a Nobel prize.
The banner for today’s post was sourced from Bradpeek
12 thoughts on “Mickey becomes more human?”
This has been troubling me for a while. Isn’t intermittent fasting supposed to increase autophagy? How come no one ever suggests it as a (relatively simple) neuroprotective strategy for PD? (One article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3106288/ … but there’s more) And yes, I get it, once you are on dopamine replacement you have to worry about what/when you eat, but a lot of us have a window BEFORE meds.
PS–someday, when you have time, I’d love to see you address the issue of ketogenesis as well. I’m in it. No problem for me, difficult for some, perhaps, but potentially useful? In your esteemed opinion, yes…no?
Interesting – but, this article seems to say that fasting is problematic for PD – but maybe i am not understanding the results correctly?
“Intermittent fasting applied in combination with rotenone treatment exacerbates dopamine neurons degeneration in mice”
“Collectively, our data suggest that, when applied in combination with neurotoxin exposure, intermittent fasting does not exert neuroprotective effects but rather exacerbate neuronal death by increasing the levels of excitatory amino acids and inflammatory lipids in association with altered brain membrane composition.”
Thanks for sharing the link – I had missed this report. I guess even if it is just an animal model, it still supports my cautious stance regarding intermittent fasting in the context of PD. I might have a deeper look into this topic – could make an interesting post.
Thanks for sharing!
Thanks for the interesting question, but given that there is very little research on this in the context of Parkinson’s AND that folks with Parkinson’s can have weight loss issues (which is usually associated with a poorer outcome), I am afraid I’m extremely reluctant to encourage the idea of intermittent fasting for PD. So I’m going to pass on giving any ‘esteemed opinion’ on this one until further research is available.
Haven’t verified it, but there has been speculation that Walt had his head (brain) frozen so as to be reincarnated when cancer is cured (Alcor maybe)????
That question is beyond my expertise I’m afraid 🙂
Simon, it seems worth noting here that the recently touted drug candidate Nilotinib has been seen in an experimental model to to promote clearing of α-synuclein by enhancing autophagy. The authors of that study also noted protection of SN neurons and amelioration of motor performance in those experiments, leading them to hypothesize those responses were direct results of that enhancement. Link: https://academic.oup.com/hmg/article/22/16/3315/627350
I like the way you think. Yes, Nilotinib – the abl inhibitor (cancer drug) being testing in PD – does appear to be an activator of autophagy (amongst other things). We discussed this in a previous post for any readers who are interested in this topic (https://scienceofparkinsons.com/2017/07/31/nilotinib-the-other-phase-ii-trial/). It would be interesting to see what happens to the ‘Lewy bodies’ in these mice if they were treated with Nilotinib (or some of the other drugs being clinically trialled for Parkinson’s, such as Ambroxol – https://scienceofparkinsons.com/2018/01/10/gsls/). These mice could be a very useful tool for the Parkinson’s research community… if these results are independently replicated.
Thanks for you comment.
As I understand the problem in the study and development of effective drugs rests on the lack of subject of experiments for scientists in the form of an exact copy of the human brain, since no animal model can reproduce exactly the organic structure of the human brain. And without such a working model, it is impossible to study the rapid development of medicines and treatments, and even just approach the understanding of brain diseases. Progress clearly rests on ethics and the norms of humanity.
I do not in any way call for cannibalistic methods, but I would like to ask a possibly naive question. Is it possible to grow the human brain from the stem cells in the foreseeable future (were there such attempts?) Or whether it is possible to restore the function of the brain after a physical death which was previously donated to science in order to study brain diseases
The EU Joint Programme – Neurodegenerative Disorders (JPND) is developping a database listing existing experimental models to study Parkinson’s disease . Development of the database is ongoing and far from being completed (only mammalian models right now but non mammalians will be added). A large number of transgenic models have already been inserted (http://www.neurodegenerationresearch.eu/models-for-parkinsons-disease/).
Importantly, the website is PUBLIC and OPEN ACESS
Your feedback is greatly appreciated (and needed). This site can only be improved through the help of all researchers so do not hesitate to visit the website, post comments and/or send information, updates on new or existing models.The model mentioned above will be inserted shortly.
Only by combining our efforts can we advance more rapidly towards the development of better treatments for PwP and eventually find disease-modifying treatments